{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-029097","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.640822+00:00","generated_at":"2026-06-05T06:38:44.352216+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"VYNE reports Q4/FY 2023 loss; cash $93.3M; VYN201 Phase 2b starts Q2 2024; VYN202 Phase 1a expected Q2 2024","bullets":["Cash, cash equivalents, restricted cash and marketable securities $93.3M at Dec 31, 2023, providing runway through end of 2025.","GAAP loss from continuing ops Q4 2023 $6.15M vs $7.76M in Q4 2022; full year $27.87M vs $33.95M (improved YoY).","Adjusted net loss Q4 2023 $5.48M vs $8.88M; full year $25.15M vs $18.91M (wider YoY for FY).","VYN201 Phase 2b trial in nonsegmental vitiligo to begin Q2 2024; top-line results mid-2025; gel formulation selected.","VYN202 IND submitted Dec 2023; FDA requested additional nonclinical study; completed consistent with expectations; Phase 1a expected Q2 2024 if FDA clears."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-029097","json":"https://secwatch.observer/filing/0001104659-24-029097.json","markdown":"https://secwatch.observer/filing/0001104659-24-029097.md","text":"https://secwatch.observer/filing/0001104659-24-029097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465924029097/0001104659-24-029097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465924029097/tm247462d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:38:44.352216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bb9ed72a3702665c3b7f96cb4b6d9751d3c99e7","claim":"VYNE Therapeutics Inc. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465924029097/0001104659-24-029097-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}